Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA’s RMAT designation and is ...
Selinexor has received three approvals but has faced disappointing sales due to competition and toxicity. Nevertheless, an already established global commercial infrastructure will support the launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results